Last reviewed · How we verify
Tegoprazan 50 mg, tablets, orally, bid — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Tegoprazan 50 mg, tablets, orally, bid (Tegoprazan 50 mg, tablets, orally, bid) — Zhang Xiaofeng,MD.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tegoprazan 50 mg, tablets, orally, bid TARGET | Tegoprazan 50 mg, tablets, orally, bid | Zhang Xiaofeng,MD | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tegoprazan 50 mg, tablets, orally, bid CI watch — RSS
- Tegoprazan 50 mg, tablets, orally, bid CI watch — Atom
- Tegoprazan 50 mg, tablets, orally, bid CI watch — JSON
- Tegoprazan 50 mg, tablets, orally, bid alone — RSS
Cite this brief
Drug Landscape (2026). Tegoprazan 50 mg, tablets, orally, bid — Competitive Intelligence Brief. https://druglandscape.com/ci/tegoprazan-50-mg-tablets-orally-bid. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab